company background image
HZNP

Horizon Therapeutics NasdaqGS:HZNP Stock Report

Last Price

US$115.60

Market Cap

US$26.5b

7D

0.3%

1Y

84.9%

Updated

20 Sep, 2023

Data

Company Financials +

Horizon Therapeutics Public Limited Company

NasdaqGS:HZNP Stock Report

Mkt Cap: US$26.5b

HZNP Stock Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases.

HZNP fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance1/6
Financial Health6/6
Dividends0/6

Horizon Therapeutics Public Limited Company Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Horizon Therapeutics
Historical stock prices
Current Share PriceUS$115.60
52 Week HighUS$115.70
52 Week LowUS$60.03
Beta1.04
1 Month Change10.12%
3 Month Change14.02%
1 Year Change84.90%
3 Year Change44.90%
5 Year Change498.34%
Change since IPO1,163.39%

Recent News & Updates

Recent updates

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Nov 25
These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Nov 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon pays HemoShear milestone payment under pact to develop gout therapies

Sep 21

Horizon Therapeutics announces $500M buyback program

Sep 09

Horizon Therapeutics to expand footprint in Ireland

Aug 29

Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Aug 22
Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Horizon Therapeutics: This Core Biotech Company Is On Sale

Aug 19

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Aug 04
Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Aug 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

Jul 31

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Jul 08

Horizon Therapeutics (NASDAQ:HZNP) Has A Rock Solid Balance Sheet

May 20
Horizon Therapeutics (NASDAQ:HZNP) Has A Rock Solid Balance Sheet

Horizon: For Those Who Dare

May 09

Here's Why I Think Horizon Therapeutics (NASDAQ:HZNP) Might Deserve Your Attention Today

May 02
Here's Why I Think Horizon Therapeutics (NASDAQ:HZNP) Might Deserve Your Attention Today

Shareholder Returns

HZNPUS BiotechsUS Market
7D0.3%-0.5%-1.5%
1Y84.9%10.8%13.8%

Return vs Industry: HZNP exceeded the US Biotechs industry which returned 8.8% over the past year.

Return vs Market: HZNP exceeded the US Market which returned 12.9% over the past year.

Price Volatility

Is HZNP's price volatile compared to industry and market?
HZNP volatility
HZNP Average Weekly Movement2.0%
Biotechs Industry Average Movement9.0%
Market Average Movement5.6%
10% most volatile stocks in US Market14.3%
10% least volatile stocks in US Market2.5%

Stable Share Price: HZNP is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: HZNP's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20052,190Tim Walberthttps://www.horizontherapeutics.com

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use.

Horizon Therapeutics Public Limited Company Fundamentals Summary

How do Horizon Therapeutics's earnings and revenue compare to its market cap?
HZNP fundamental statistics
Market CapUS$26.47b
Earnings (TTM)US$438.00m
Revenue (TTM)US$3.64b

60.4x

P/E Ratio

7.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HZNP income statement (TTM)
RevenueUS$3.64b
Cost of RevenueUS$824.98m
Gross ProfitUS$2.82b
Other ExpensesUS$2.38b
EarningsUS$438.00m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.91
Gross Margin77.36%
Net Profit Margin12.02%
Debt/Equity Ratio48.2%

How did HZNP perform over the long term?

See historical performance and comparison